Sunovion intros Kynmobi

Sunovion Pharmaceuticals is introducing Kynmobi (apomorphine HCI) sublingual film for the acute, intermittent treatment of off episodes in patients with Parkinson’s disease.

It is the first and only sublingual therapy for the on-demand treatment of offepisodes in patients with Parkinson’s disease, the company said.

The Food and Drug Administration gave Sunovion the green light for the product on May 21, 2020 and its commercial activities initiated on Sept. 29, 2020.

“People living with Parkinson’s disease can potentially spend hours each day navigating disruptions caused by off episodes, which may result in reduced motor function and present challenges performing daily activities,” said Thomas Gibbs, senior vice president, chief commercial officer at Sunovion. “Off episodes can make simple tasks, like getting dressed in the morning, nearly impossible. We are pleased that patients, their care partners and physicians now have access to Kynmobi to help control these debilitating off episodes.”

“Reduced mobility associated with off episodes can be one of the most troubling and burdensome aspects for people living with Parkinson’s disease,” said Stuart Isaacson, director of Parkinson’s Disease and Movement Disorders Center of Boca Raton. “This is intensified as Parkinson’s disease progresses and off episodes become more frequent. The availability of Kynmobi provides a new, effective on-demand treatment option that we can offer patients to use as needed for off episodes when they occur.”